The immunoblot program described here has got the capacity to recognize TKI resilient subclones, including CML cells with Bcr Abl variations. In addition, our method appears to need smaller population of TKI resistant subclones than Bcr Abl sequence analysis and examine Bcr Abl action more directly than the IC50. Ergo, when applied together with the cellular IC50 values and Bcr Abl collection, this immunoblot process should help increase the treatment of patients with CML. It is now well established that angiogenesis is critical for a tumor to grow beyond a certain size. Angiogenesis isn’t only needed ALK inhibitor for solid tumors but also plays a crucial role in hematologic malignancies. Several groups have seen increased microvessel density in bone marrow samples from patients with ALL and acute myeloid leukemia. Angiogenesis in both normal and infection tissues is influenced by the net balance between proand anti angiogenic facets. Among the numerous factors, the vascular endothelial growth factor has demonstrated an ability to play a key role. Lately, VEGF has been reported to be described as a putative biomarker crucial in hematopoietic malignancies. NHE1 is just a ubiquitously expressed person in the Na /H exchanger household that catalyzes the extrusion Plastid of intracellular proton ions in trade for extracellular sodium ions, thereby regulating intracellular pH. It has been demonstrated that elevations in pHi are directly linked with the growth pathologic processes such as actions of several growth factors and oncogenes, DNA synthesis, cell transformation and growth, the metastatic process, and multiple drug resistance. A recent survey has revealed that inhibition of NHE1 may down-regulate the expression of VEGF in vitro. However, if this inhibition is adequate enough to inhibit tumor angiogenesis in vivo is not confirmed. In this study, we discover the effect of selective NHE1 chemical cariporide on migration and growth of the endothelial cell HUVEC in vitro, and OSI-420 EGFR inhibitor confirm the anti angiogenetic effect of cariporide in vitro and in vivo. We purchased RPMI 1640 media from Gibco BRL Life Technologies, Inc., fetal bovine serum and medium 199 from HyClone, 2, 7 bis 5 carboxyfluorescein acetoxymethyl, and cariporide from Sigma, Enhanced Chemiluminescence Reagent Plus reagents from BD Transduction Laboratories. Polyclonal rabbit anti human VEGF antibodies and horseradish peroxidase conjugated IgG goat anti rabbit antibodies were obtained from Santa Cruz Biotechnology, mouse monoclonal antibody to the CD31 antigen from PharMingen, biotin labeled goat anti mouse IgG from Zymed, ELISA set particular for human VEGF was purchased from R&D systems, Recombinant human VEGF 165 was purchased from Sino Biological Inc, transwell chamber was purchased from Corning Costar Corp, matrigel was purchased from BD Bioscience.